Fulcrum Therapeutics used its presentation at ASH for its sickle cell disease drug as a springboard for raising US$175m from a one-day marketed follow-on, a more modest (than Terns) 16.7% upsize from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback